Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesBIIB021, a synthetic HSP90 inhibitor, has broad application against tumors with acquired multidrug resistance
International Journal of Cancer, 09/29/09
Zhang H et al. – These data indicate that the new generation of synthetic anti–Hsp90 drugs, exemplified by BIIB021 that is currently undergoing Phase II testing, may have broader application against tumors with acquired multidrug resistance or tumors located in organs protected by MDR proteins, such as the adrenal glands, brain and testis.
Hong Zhang, 09/29/09
| BIIB021 is the first synthetic Hsp90 small molecule inhibitor that enters clinical trial. Compare to the nature Hsp90 inhibitor and its derivatives, BIIB021 is not affected by the expression of multidrug resistant proteins. This implies that the small molecule inhibitor may have a broad apectrum of antitumor activity, considering that a significant amount of cancers express MDR or its related proteins, either by nature or acquired during previous treatment. |
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Two antimalaria drugs are tolerated regimens in regions with resistance
Formulary , 12/02/09
Imipenem Resistance in Pseudomonas aeruginosa: Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes
Infection Control and Hospital Epidemiology, 12/02/09
Sponsor
Article Search
Sponsor